Send the following on WhatsApp
Continue to ChatInterim analysis of a prospective, randomized, double blind, placebo controlled, phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected stage III or IV melanoma patients. https://www.sages.org/meetings/annual-meeting/abstracts-archive/interim-analysis-of-a-prospective-randomized-double-blind-placebo-controlled-phase-iib-trial-of-the-tlpldc-vaccine-to-prevent-recurrence-in-resected-stage-iii-or-iv-melanoma-patients/